TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18971325

Group type: EXPERIMENTAL
Intervention: AVN944 (doses ranging from 25 to 250 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AVN944 (doses > 100 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AVN944 (with fasting)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (2 doses, one with food and one after fasting)
Number of subjects: 25
Study: 17762749

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 42
Study: 15211696

Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride (CH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11167281

Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone acetate (steroid group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine (NSAID group)
Number of subjects: 80
Study: 9778226

Group type: EXPERIMENTAL
Intervention: Methotrexate, sulfasalazine, or both (exact dosages not specified)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Methotrexate, sulfasalazine, or both
Number of subjects: 105
Study: 8089282

Group type: EXPERIMENTAL
Intervention: 5% FDO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 2842882

Group type: EXPERIMENTAL
Intervention: BCAA-enriched solution
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional amino acid solution (Control)
Number of subjects: 56
Study: 30302877

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 211
Study: 26685122

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg.kg(‐1) (high dose group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg.kg(‐1) (middle dose group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg.kg(‐1) (low dose group)
Number of subjects: 50
Study: 25373320

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1,000 mg iron)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 22523159

Group type: EXPERIMENTAL
Intervention: Glycerin hydrogel (GHG) wound dressing
Number of subjects: 68
Study: 20212264

Group type: EXPERIMENTAL
Intervention: DASH diet with aerobic exercise and caloric restriction
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DASH diet alone
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual diet controls (UC)
Number of subjects: 144
Study: 18403746

Group type: EXPERIMENTAL
Intervention: PT+AO(congruent)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PT+AO(incongruent)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 8
Study: 16368047

Group type: EXPERIMENTAL
Intervention: DDTDF (Durogesic D‐TRANS fentanyl Matrix Delivery System)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transdermal reservoir system (fentanyl transdermal reservoir)
Number of subjects: 80
Study: 12889679

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10471635

Group type: EXPERIMENTAL
Intervention: aerosolized E25 1 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: aerosolized E25 10 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: aerosolized placebo
Number of subjects: 33
Study: 8609344

Group type: EXPERIMENTAL
Intervention: L-arginine (20 g/day for 28 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle syrup in equal amounts)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (healthy individuals)
Number of subjects: 20
Study: 2031820

Group type: COMPARATOR
Intervention: aminophylline 2 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: flumazenil 0.01 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo saline 0.1 ml kg‐1
Number of subjects: 60
Study: 7013893

Group type: EXPERIMENTAL
Intervention: Intra-incisional cefuroxime (n = 26)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Systemic cefuroxime (n = 27)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 81
Study: 29912679

Group type: EXPERIMENTAL
Intervention: Oral indomethacin (IDC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral ibuprofen (IB)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral indomethacin (IDC) in extremely low-birthweight infants (<1000 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral ibuprofen (IB) in extremely low-birthweight infants (<1000 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral indomethacin (IDC) and Oral ibuprofen (IB)
Number of subjects: 32
Study: 27342501

Group type: EXPERIMENTAL
Intervention: CIK+IL-2
Number of subjects: 170
Study: 24842181

Group type: EXPERIMENTAL
Intervention: Targeted intracluster-injection (TII) technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Double-injection (DI) technique
Number of subjects: 90
Study: 21638755

Group type: EXPERIMENTAL
Intervention: Deferasirox treatment (25 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no iron chelation treatment)
Number of subjects: 20
Study: 19174783

Group type: EXPERIMENTAL
Intervention: Stepwise circumferential and focal ablation using the HALO system
Number of subjects: 63
Study: 17196682

Group type: EXPERIMENTAL
Intervention: Nicorandil (4 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cocktail (normal saline + 200 microg of verapamil)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 150
Study: 15190527

Group type: EXPERIMENTAL
Intervention: MVR surgery plus the CorCap Cardiac Support Device (CSD)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CSD implant plus optimal medical therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 300

Group type: COMPARATOR
Intervention: MVR surgery alone
Number of subjects: 300
Study: 12184424

Group type: EXPERIMENTAL
Intervention: K‐file or K‐Nitiflex file (step‐back technique)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: K‐reamer (standardization technique)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Irrigation only
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study: 9615870

Group type: EXPERIMENTAL
Intervention: Energy restricted diet (75% kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance energy diet (100% kcal)
Number of subjects: 0
Study: 7653770

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg intravenously 20 min prior to the end of surgery and a patient‐controlled analgesia infusion containing morphine 1 mg.ml‐1 and droperidol 0.05 mg.ml‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cyclizine 50 mg by slow intravenous injection 20 min prior to the end of surgery and a patient‐controlled analgesia infusion containing morphine 1 mg.ml‐1 and cyclizine 2 mg.ml‐1
Number of subjects: 50
Study: 2583908

Group type: EXPERIMENTAL
Intervention: PUVA therapy
Number of subjects: 12
Study: 338024

Group type: EXPERIMENTAL
Intervention: Oestradiol, 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestriol, 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29509645

Group type: EXPERIMENTAL
Intervention: Telephone call before UDS appointment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care (no telephone call)
Number of subjects: 102
Study: 29154060

Group type: EXPERIMENTAL
Intervention: Cholesfytol® (1 tablet/day)
Number of subjects: 642
Study: 25745750

Group type: EXPERIMENTAL
Intervention: Vaginoscopy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional hysteroscopy
Number of subjects: 90
Study: 23077975

Group type: EXPERIMENTAL
Intervention: False isolated-office RH (elevated clinic BP, controlled awake SBP/DBP means, but elevated asleep SBP or DBP mean)
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: True isolated-office RH (elevated clinic BP and controlled awake and asleep ambulatory BPs)
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: True RH (elevated awake or asleep SBP/DBP means while treated with 3 medications, or any patient treated with ≥4 medications)
Number of subjects: 3042
Study: 20573655

Group type: EXPERIMENTAL
Intervention: Naloxone (IV injection of two 0.4 mg ampules)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 116
Study: 19880280

Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion (CV)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Conventional approach without TEE
Number of subjects: 366
Study: 16533781

Group type: EXPERIMENTAL
Intervention: 1,200 mg orally once daily (arm A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1,200 mg orally twice daily (arm B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 80
Study: 15545973

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by tamoxifen for 5 years
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Tamoxifen for 5 years
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Number of subjects: 1669
Study: 10903249

Group type: EXPERIMENTAL
Intervention: OSA‐Monobloc
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OSA‐Herbst
Number of subjects: 24

Group type: COMPARATOR
Intervention: No appliance
Number of subjects: 24
Study: 9120789

Group type: EXPERIMENTAL
Intervention: Large monetary reward for novel performance
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Reward for novel performance
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Reward for uncreative performance
Number of subjects: 416
Study: 8463435

Group type: COMPARATOR
Intervention: Single dose of 60 mg diltiazem
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diltiazem 60 mg three times a day for 3 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diltiazem 60 mg three times a day for 6 days
Number of subjects: 18
Study: 3903868

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0
Study: 31390641

Group type: EXPERIMENTAL
Intervention: Telemedicine care (TC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 75
Study: 30043039

Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (n=191)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) (n=203)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (n=41)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) (n=38)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab
Number of subjects: 394

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 394
Study: 27412638

Group type: EXPERIMENTAL
Intervention: Kangaroo Ward Care (KWC)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Intermediate Intensive Care (IIC)
Number of subjects: 141
Study: 24859122

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion program consisting of breast massage and 1:1 breastfeeding education, counseling, and support for 10 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 70
Study: 22391283

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study: 20109275

Group type: EXPERIMENTAL
Intervention: Above average students
Number of subjects: 382

Group type: COMPARATOR
Intervention: Average students
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Below average students
Number of subjects: 382
Study: 18313127

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/d
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15827314

Group type: EXPERIMENTAL
Intervention: Pnc9-MenC (n = 120)
Number of subjects: 240

Group type: COMPARATOR
Intervention: MenC (n = 120)
Number of subjects: 240
Study: 12055580

Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine (0.5 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 28
Study: 10982577

Group type: EXPERIMENTAL
Intervention: Specially developed pamphlet
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: EPA's 'A citizen's guide to radon'
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Brief telephone counselling
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Specially developed pamphlet plus brief telephone counselling
Number of subjects: 714
Study: 9124917

Group type: EXPERIMENTAL
Intervention: Superior septal approach
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional left atriotomy
Number of subjects: 146
Study: 8442622

Group type: EXPERIMENTAL
Intervention: Nurse-assisted self-quit training
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Nurse-assisted group referral
Number of subjects: 3161

Group type: EXPERIMENTAL
Intervention: Nurse-assisted combination of self-quit training and referral
Number of subjects: 3161

Group type: COMPARATOR
Intervention: Brief physician advice alone
Number of subjects: 3161
Study: 3009292

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29175067

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol (528 women)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: GnRH agonist protocol (495 women)
Number of subjects: 1023
Study: 27529375

Group type: EXPERIMENTAL
Intervention: Lurasidone (20-60 mg/d or 80-120 mg/d)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lurasidone (20-120 mg/d)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 23912215

Group type: EXPERIMENTAL
Intervention: Cementless THA
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cemented THA
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 22388491

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (doses of 2, 4, 6, 8, and 10 mg·kg bm(‐1))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20102356

Group type: EXPERIMENTAL
Intervention: Satavaptan 5 mg once daily
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Satavaptan 12.5 mg once daily
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg once daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 17262795

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate at a dose of 440 mg/m²/day for 28 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 70
Study: 16846420

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 120

Group type: COMPARATOR
Intervention: CCAB
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 12784170

Group type: EXPERIMENTAL
Intervention: Maximal isometric voluntary contraction and flexibility measured with specific ergometers; muscle stiffness measured using quick-release movements of the wrist.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexibility assessments in both women groups; training-induced increase for wrist extension.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women active joint flexibility and musculo-tendinous stiffness indices.
Number of subjects: 0
Study: 10770462

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.5 mg twice daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 8777275

Group type: EXPERIMENTAL
Intervention: Measurement of IL‐1 beta in gingival crevicular fluid (GCF) and inflamed gingival specimens using ELISA.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GCF flow measurement.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Correlation analysis of IL‐1 beta concentration with tissue pathology.
Number of subjects: 14
Study: 29716819

Group type: EXPERIMENTAL
Intervention: Metered-Dose Inhaler (MDI)
Number of subjects: 890

Group type: COMPARATOR
Intervention: Breath Actuated Nebulizer (BAN)
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Adjusted analysis for MDI
Number of subjects: 890

Group type: COMPARATOR
Intervention: Adjusted analysis for BAN
Number of subjects: 890
Study: 27429037

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25259643

Group type: EXPERIMENTAL
Intervention: Homecare training
Number of subjects: 12
Study: 22051940

Group type: EXPERIMENTAL
Intervention: Basic Plus (n = 137) - PCP counseling every 4 months plus monthly LC visits during the first year of treatment
Number of subjects: 261

Group type: COMPARATOR
Intervention: Basic (n = 124) - PCP counseling every 4 months only
Number of subjects: 261
Study: 20613460

Group type: EXPERIMENTAL
Intervention: Salsalate (anti-inflammatory treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 17663101

Group type: EXPERIMENTAL
Intervention: Acupoint-injection of BCG polysaccharide nuclear acid (BCG-PSN)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular injection of BCG-PSN
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular injection of interferon
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment (blank control group)
Number of subjects: 200
Study: 16105152

Group type: EXPERIMENTAL
Intervention: Sotalol 100 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Lignocaine 100 mg
Number of subjects: 129
Study: 12139216

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (200 mg for 3 days)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Quinfamide (100 mg for 1 day), mebendazole (200 mg for 3 days), or both
Number of subjects: 275
Study: 10199534

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg) before cardiopulmonary bypass and before declamping of the aorta (MPS group, n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 7882789

Group type: EXPERIMENTAL
Intervention: Primary repair of colon injuries
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fecal diversion
Number of subjects: 200
Study: 2182822

Group type: EXPERIMENTAL
Intervention: Aversive taste and reward system
Number of subjects: 22
Study: 437665

Group type: EXPERIMENTAL
Intervention: Actovegin forte dragées, 2 dragées three times daily for six weeks
Number of subjects: 70
Study: 30597025

Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (35 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard rifampicin (10 mg/kg daily)
Number of subjects: 0
Study: 28011099

Group type: EXPERIMENTAL
Intervention: Walking program (70 min/week of at least moderate intensity)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study: 25881975

Group type: EXPERIMENTAL
Intervention: Citrate-based anticoagulation (RCA)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 103
Study: 23703406

Group type: EXPERIMENTAL
Intervention: Percutaneous neurolysis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21112671

Group type: EXPERIMENTAL
Intervention: 0.2% nitrofurazone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.1% polihexanide
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Number of subjects: 71
Study: 19174717

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macular grid laser photocoagulation (GLP)
Number of subjects: 30
Study: 16882889

Group type: EXPERIMENTAL
Intervention: Eccentric strength training (squats on a 25 degrees decline board, 3 sets of 15 repetitions, twice daily for 12 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Surgical treatment (open patellar tenotomy with rehabilitation)
Number of subjects: 35
Study: 14687242

Group type: EXPERIMENTAL
Intervention: SGA group (n = 18)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ex-preterm group (n = 15)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Controls (n = 17)
Number of subjects: 50
Study: 11748758

Group type: EXPERIMENTAL
Intervention: acute levodopa (L-dopa) challenge
Number of subjects: 1

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1
Study: 9269364

Group type: EXPERIMENTAL
Intervention: 100 mg suppository diclofenac before surgical incision and morphine infusion 1.5 mg per hour postoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine infusion 1.5 mg per hour postoperatively
Number of subjects: 60
Study: 8111804

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg BID
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg BID
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 3448989

Group type: EXPERIMENTAL
Intervention: Smooth Kirschner wires
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Threaded Kirschner wires
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cortical screw
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 86
Study: 29746536

Group type: EXPERIMENTAL
Intervention: Weight loss attempts
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Following a specific dietary regimen
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Self-identification as overweight
Number of subjects: 555
Study: 27100753

Group type: EXPERIMENTAL
Intervention: 450 cc blood donation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no blood donation)
Number of subjects: 0
Study: 25715047

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52